CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

被引：124
|
作者：
Maisey, NR [1 ]
Norman, AR [1 ]
Hill, A [1 ]
Massey, A [1 ]
Oates, J [1 ]
Cunningham, D [1 ]
机构：
[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England
来源：
BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 07期
关键词：
pancreatic cancer; CA19-9; prognosis; chemotherapy;
D O I：
10.1038/sj.bjc.6602760
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3 - 2.5, P = 0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS ( HR 1.9; 95% CI: 1.1 - 3.4, P = 0.019).
引用
收藏
页码：740 / 743
页数：4
相关论文
共 50 条
  • [41] Comparison of Plasma Tu-M2-PK and CA19-9 in Pancreatic Cancer
    Joergensen, Maiken Thyregod
    Heegaard, Niels H. H.
    de Muckadell, Ove B. Schaffalitzky
    PANCREAS, 2010, 39 (02) : 243 - 247
  • [42] Exploration of the value of MRCP combined with tumor marker CA19-9 in the diagnosis of pancreatic cancer
    Ma, Shaojun
    Duan, Jutao
    Li, Weizhi
    Zhang, He
    Hou, Zhenyu
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2016, 44 (02) : 717 - 721
  • [43] CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis
    Ji-Cong Gui
    Wei-Li Yan
    Xing-Dang Liu
    Clinical and Experimental Medicine, 2014, 14 : 225 - 233
  • [44] CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis
    Gui, Ji-Cong
    Yan, Wei-Li
    Liu, Xing-Dang
    CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 14 (02) : 225 - 233
  • [45] Combination of neutrophil-to-lymphocyte ratio and serum CA 19-9 as a prognostic factor in pancreatic cancer
    Garcia-Herrera, Juan Sebastian
    Munoz-Montano, Wendy R.
    Lopez-Basave, Horacio N.
    Morales-Vasquez, Flavia
    Castillo-Morales, Carolina
    Rivera-Mogollan, Luis G.
    Hernandez-Castaneda, Karla F.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04) : 1805 - 1819
  • [46] Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer
    Kochi M.
    Fujii M.
    Kanamori N.
    Kaiga T.
    Kawakami T.
    Aizaki K.
    Kasahara M.
    Mochizuki F.
    Kasakura Y.
    Yamagata M.
    Gastric Cancer, 2000, 3 (4) : 177 - 186
  • [47] Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer
    Zhao, Yun-Peng
    Zhou, Ping-Ting
    Ji, Wei-Ping
    Wang, Hao
    Fang, Meng
    Wang, Meng-Meng
    Yin, Yue-Peng
    Jin, Gang
    Gao, Chun-Fang
    CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 17 (01) : 9 - 18
  • [48] Prognostic Value of Changes in Preoperative and Postoperative Serum CA19-9 Levels in Gastric Cancer
    Song, Xiao-Hai
    Liu, Kai
    Yang, Shi-Jie
    Zhang, Wei-Han
    Chen, Xiao-Long
    Zhao, Lin-Yong
    Chen, Xin-Zu
    Yang, Kun
    Zhou, Zong-Guang
    Hu, Jian-Kun
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [49] Clinical Significance of CA19-9 in the Follow-Up of Colorectal Cancer Patients with Elevated Preoperative Serum CA19-9
    Yang, Shung-Haur
    Jiang, Jeng -Kai
    Chang, Shih-Ching
    Huang, Chi-Jung
    Lin, Jen-Kou
    HEPATO-GASTROENTEROLOGY, 2013, 60 (125) : 1021 - 1027
  • [50] CA19-9 as a Predictor of Resectability in Patients with Borderline Resectable Pancreatic Cancer
    He, Zhaopeng
    Lu, Huimin
    Du, Xiaojiong
    Hu, Weiming
    Tian, Bole
    Zhang, Zhaoda
    HEPATO-GASTROENTEROLOGY, 2013, 60 (124) : 900 - 903
12345